Granite Bio Funding: $100M Raised, Series B (2025)
Granite Bio is a Biotech company. It has raised $100M in total funding. Latest round: Series B. Backed by Versant Ventures, Novartis Venture Fund, Forbion.
Granite Bio funding overview
Granite Bio is a Biotech company. Granite Bio has raised $100M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in April 2025. The round record for Granite Bio runs through 2025; nothing later has been disclosed. Investors on record include Versant Ventures, Novartis Venture Fund, Forbion, Sanofi Ventures. 4 distinct backers are named across the disclosed rounds.
Granite Bio has raised $100M in total disclosed funding across the rounds on record.
Who has invested in Granite Bio?
Versant Ventures, Novartis Venture Fund, Forbion, Sanofi Ventures are named among the investors backing Granite Bio.
What was the latest Granite Bio funding round?
The most recent disclosed round is a Series B, announced in April 2025.
Where is Granite Bio based?
No headquarters location is disclosed for Granite Bio.
What sector does Granite Bio operate in?
Granite Bio is tracked under Biotech, with $100M in disclosed funding.
When did Granite Bio last raise?
The last disclosed Granite Bio round closed in April 2025 at Series B.
Round data for Granite Bio is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the Biotech companies and backer lists below.
